We have taught medicine in Newcastle since 1834. We are proud of our rich and vibrant history, which provides a strong foundation for innovation and growth.
We excel in tackling challenges in health and healthcare. We're at the forefront of the translational medicine revolution.
We turn scientific advances into direct benefits for patients. We enjoy strong partnerships with local NHS Trusts.
Our work has led to major advances in patient healthcare regionally, nationally and internationally.
Our Institutes
World-class, research-led teaching
We have a long-standing reputation for being one of the best places to study medical and health sciences.
We rank highly across both international and national league tables.
We support undergraduate and postgraduate students studying both taught and research programmes.
National project aims to improve students’ mental health
Students are being encouraged to take part in Nurture-U, a national project which aims to improve their mental health at university.
Budget boost to help put health at the heart of Newcastle’s future
A pioneering development aimed at tackling health and social challenges that will benefit people in the North East and beyond has been given a funding boost in today’s budget.
Newcastle academic pays tribute to his friend Hairy Biker Dave Myers
A leading academic who helped Hairy Byker Dave Myers reverse his type 2 diabetes has paid tribute to the “loyal friend to all”.
Research-intensive universities generate nearly £38 bn for UK economy
A new report assessing the economic impact of the Russell Group universities, found that for every £1 of public funds invested in research, more than £8.50 was generated for the UK economy.
Architecture formed of fungal mycelium is growing in Newcastle
The Growing Room will be exhibited as part of the Edinburgh Science Festival.
Diet links to longer remissions of type 2 diabetes and improved health
An extension of the landmark Diabetes Remission Clinical Trial DiRECT reveals that, for those in remission from type 2 diabetes at the end of year two, 26% still remained in remission at year five.